Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Busulfan Plus Melphalan Versus Melphalan
This study is currently recruiting participants.
Verified April 2013
by M.D. Anderson Cancer Center
Study NCT01413178 Information provided by M.D. Anderson Cancer Center
First Received on August 8, 2011. Last Updated on April 15, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myeloma
Additional conditions recognized in this trial
Multiple Myeloma
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Busulfan
Melphalan
Questionnaire
G-CSF
High Dose Melphalan
Stem cell transplant
Additional drug interventions recognized in this trial
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.
Back to top of Main Content
